{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:31:54Z","timestamp":1790314314995,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bioorg.2026.109939","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T22:15:41Z","timestamp":1777846541000},"page":"109939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["New pyrimidine compounds as potent anti-breast cancer agents: synthesis, biological evaluation and computational studies"],"prefix":"10.1016","volume":"178","author":[{"given":"Niteen R.","family":"Sutar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar G.","family":"Alegaon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Gharge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shriram D.","family":"Ranade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen A.","family":"Kamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109939_bb0010","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-025-13730-y","article-title":"Incidence trends of early-onset breast cancer by lifestyle risk factors","volume":"25","author":"Rantala","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2026.109939_bb0015","article-title":"Chemotherapy treatment and strategy schemes: a review","volume":"2","author":"Alam","year":"2018","journal-title":"Open Access J. Toxicol."},{"key":"10.1016\/j.bioorg.2026.109939_bb0020","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109939_bb0025","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.109939_bb0030","article-title":"A review on the role of cyclin dependent kinases in cancers","volume":"22","author":"Ghafouri-Fard","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bioorg.2026.109939_bb0035","doi-asserted-by":"crossref","DOI":"10.4172\/1948-5956.1000408","article-title":"Cyclic dependent kinase (CDK): role in cancer pathogenesis and as drug target in cancer therapeutics","volume":"8","author":"Geleta","year":"2016","journal-title":"J. Cancer Sci. Ther."},{"key":"10.1016\/j.bioorg.2026.109939_bb0040","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.drudis.2019.12.001","article-title":"Targeting CDK2 in cancer: challenges and opportunities for therapy","volume":"25","author":"Tadesse","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2026.109939_bb0045","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/14728222.2025.2537412","article-title":"Targeting CDK2 and other novel cell cycle targets for breast cancer therapy","volume":"29","author":"Chen","year":"2025","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bioorg.2026.109939_bb0050","series-title":"CDK inhibitors in cancer therapy, an overview of recent development","volume":"vol. 11","author":"Zhang","year":"2021"},{"key":"10.1016\/j.bioorg.2026.109939_bb0055","series-title":"NU-6027 inhibits growth of Mycobacterium tuberculosis by targeting Protein Kinase D and Protein Kinase G","author":"Kidwai","year":"2019"},{"key":"10.1016\/j.bioorg.2026.109939_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/ph17010104","article-title":"Recent advances in pyrimidine-based drugs","volume":"17","author":"Nammalwar","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2026.109939_bb0065","series-title":"Send Orders for Reprints to reprints@benthamscience.net Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents","volume":"vol. 22","author":"Ali Chohan","year":"2015"},{"key":"10.1016\/j.bioorg.2026.109939_bb0070","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1021\/acs.jmedchem.8b01469","article-title":"Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update","volume":"62","author":"Tadesse","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109939_bb0075","doi-asserted-by":"crossref","DOI":"10.1186\/s43094-021-00274-8","article-title":"Pyrimidine: a review on anticancer activity with key emphasis on SAR","volume":"7","author":"Mahapatra","year":"2021","journal-title":"Futur. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2026.109939_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/cimb47060454","article-title":"Development of CDK4\/6 inhibitors in gastrointestinal cancers: biomarkers to move forward","volume":"47","author":"Voutsadakis","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.109939_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2015.00016","article-title":"Targeting cell cycle regulators in hematologic malignancies","volume":"3","author":"Aleem","year":"2015","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bioorg.2026.109939_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108306","article-title":"Design, synthesis and molecular dynamics simulations of thiazole-based hydrazones targeting MDA-MB-231 breast cancer cells","volume":"157","author":"Alegaon","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109939_bb0095","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.109939_bb0100","doi-asserted-by":"crossref","DOI":"10.1007\/s13721-024-00451-8","article-title":"Computational screening identifies depsidones as promising Aurora A kinase inhibitors: extra precision docking and molecular dynamics studies","volume":"13","author":"Almogaddam","year":"2024","journal-title":"Netw. Model. Anal. Health Inform. Bioinform."},{"key":"10.1016\/j.bioorg.2026.109939_bb0105","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jmgm.2009.08.012","article-title":"Induced-fit docking studies of the active and inactive states of protein tyrosine kinases","volume":"28","author":"Zhong","year":"2009","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.bioorg.2026.109939_bb0110","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening","volume":"47","author":"Halgren","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109939_bb0115","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","article-title":"OPLS3: a force field providing broad coverage of drug-like small molecules and proteins","volume":"12","author":"Harder","year":"2016","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.bioorg.2026.109939_bb0120","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/10799893.2019.1585453","article-title":"Molecular docking, 3D-QSAR, molecular dynamics, synthesis and anticancer activity of tyrosine kinase 2 (TYK 2) inhibitors","volume":"38","author":"Itteboina","year":"2018","journal-title":"J. Recept. Signal Transduction"},{"key":"10.1016\/j.bioorg.2026.109939_bb0125","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.compbiolchem.2018.03.001","article-title":"Design, facile synthesis, and evaluation of novel spiro- and pyrazolo[1,5-c]quinazolines as cholinesterase inhibitors: molecular docking and MM\/GBSA studies","volume":"74","author":"G\u00e1lvez","year":"2018","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.109939_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.133701","article-title":"New phosphinic and phosphonic acids: synthesis, antidiabetic, anti-Alzheimer, antioxidant activity, DFT study and SARS-CoV-2 inhibition","volume":"1268","author":"Elkolli","year":"2022","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.109939_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116939","article-title":"Reversal of insulin resistance to combat type 2 diabetes mellitus by newer thiazolidinedione\u2019s in fructose induced insulin resistant rats","volume":"280","author":"Ranade","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109939_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.144867","article-title":"Development and evaluation of exosome-encapsulated lenvatinib\/h-BN nanocomposites for targeted chemo-photothermal therapy of hepatocellular carcinoma with enhanced pharmacokinetics","volume":"1354","author":"Elbeltagi","year":"2026","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.109939_bb0145","article-title":"Repositioning of rhodanine-thiazole hybrids as aldose reductase inhibitors","volume":"27","author":"Gharge","year":"2025","journal-title":"Med. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.109939_bb0150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10822-025-00645-w","article-title":"Computational and experimental repositioning of quinoline analogues as KSP inhibitors: insights from free energy landscape and PCA analysis","volume":"39","author":"Alegaon","year":"2025","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.bioorg.2026.109939_bb0155","article-title":"Apoptosis induction and anti-inflammatory cytokines effects of sorafenib-loaded MXene-UiO-66@ liposome nanocomposites in liver cancer under NIR irradiation","author":"Elbeltagi","year":"2025","journal-title":"Diam. Relat. Mater."},{"key":"10.1016\/j.bioorg.2026.109939_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125492","article-title":"Multifunctional sorafenib-loaded MXene for enhanced cancer therapy: in vitro and in vivo study based on chemotherapy\/photothermal therapy approach","volume":"674","author":"Elbeltagi","year":"2025","journal-title":"Int. J. Pharm."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600475X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600475X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T08:46:43Z","timestamp":1779698803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682600475X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"alternative-id":["S004520682600475X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109939","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New pyrimidine compounds as potent anti-breast cancer agents: synthesis, biological evaluation and computational studies","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109939","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109939"}}